Acta Marisiensis - Seria Medica (Dec 2023)

Adrenocortical carcinoma: A tumor with poor answer to classic chemotherapy

  • Sava Alexandra Daniela,
  • Szekely Tiberiu Bogdan,
  • Togănel Cornelia,
  • Vacar Adela,
  • Gurzu Simona

DOI
https://doi.org/10.2478/amma-2023-0039
Journal volume & issue
Vol. 69, no. 4
pp. 292 – 294

Abstract

Read online

Introduction: Adrenocortical carcinoma (ACC) represents a rare endocrine malignancy being the second most aggressive endocrine cancer after anaplastic thyroid cancer. [1]. While most of them arise sporadically, up to 15% of adult ACC patients are related to germline mutations associated with familial cancer syndromes.[1,2]. Current treatment strategies include surgery as well as systemic therapy with mitotane and chemotherapy.

Keywords